| --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The Power of a 12-Lead ECG Always with the patient | | | | | | | | | | | | | | Fourth Quarter & Full Year 2023 Financial Results Conference Call | | | | | | | NASDAQ: BEAT March 20, 2024 | | | | | | Fourth Quarter 2023 Financial Results Conference Call 2 DISCLAIMERS This presentation contai ...

Start Time: 16:30 January 1, 0000 5:11 PM ET HeartBeam, Inc. (NASDAQ:BEAT) Q4 2023 Earnings Conference Call March 20, 2024, 16:30 PM ET Company Participants Branislav Vajdic - CEO and Founder Rob Eno - President Deborah Castillo - VP of Regulatory Affairs Rick Brounstein - Consulting CFO Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings, and welcome to the HeartBeam Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in ...

We are applying for 510(k) clearance for the AIMIGo system. To obtain 510(k) clearance, a company must submit a notification to the FDA demonstrating that its proposed device is substantially equivalent to a predicate device (i.e., a device that was in commercial distribution before May 28, 1976, a device that has been reclassified from Class III to Class I or Class II, or a 510(k)-cleared device). The FDA's 510(k) clearance process generally takes from three to 12 months from the date the application is su ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of the AIMIGo 12-Lead ECG Synthesis Software for Arrhythmia Detection) pivotal study. The first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, GA. The VALID-ECG study will evaluate ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office. HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-l ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday March 20, 2024 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issu ...

Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett. To the Shareholders of MDB Capital Holdings, LLC: Welcome to our first annual letter, which I plan to send every January to reflect on the past year and how w ...

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Rob Eno - President Rick Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conf ...

The Power of a 12L ECG Always with the patient | | Third Quarter 2023 Financial Results Conference Call NASDAQ: BEAT November 14, 2023 Third Quarter 2023 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives o ...

14 We do not hold any derivative instruments and do not engage in any hedging activities. Item 4. Controls and Procedures. Disclosure Controls and Procedures Table of contents PART II-OTHER INFORMATION Not applicable. Not applicable. Item 5. Other Information. 17 Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimate ...